Boston Sci leads $10M round for Securus Medical

Securus Medical, which is developing a real-time thermal mapping system to measure core body temperature, raised $10 million in a Series C round led by Boston Scientific. The funding will go toward further product development and clinical investigation of its device.

The device, the infrared thermographic system (IRTS), recently received FDA clearance, the company said in a statement. It is an intrabody thermal measurement device intended for the continuous monitoring of esophageal temperature.

In addition to Boston Scientific, existing investors RiverVest Venture Partners, 3X5 Special Opportunity Fund and the University of Michigan’s Investment in New Technology Startups (MINTS) program also participated in the round.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

"This financing accelerates Securus Medical Group's technology development, and importantly it enables further validation of the Company's core technology which holds great potential to change the standard of care for esophageal temperature monitoring,” said Karen Spilizewski, RiverVest Venture Partners vice president and a Securus board member, in the statement.

The company previously raised $6.5 million in a 2013 Series B round.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.